Cullinan Oncology (NASDAQ:CGEM) Receives New Coverage from Analysts at Stifel Nicolaus

Stifel Nicolaus started coverage on shares of Cullinan Oncology (NASDAQ:CGEM) in a research note released on Wednesday morning, Marketbeat.com reports. The brokerage issued a buy rating and a $40.00 target price on the stock.

Several other research analysts have also recently weighed in on CGEM. HC Wainwright lowered their price target on shares of Cullinan Oncology from $34.00 to $29.00 and set a buy rating on the stock in a report on Tuesday, April 16th. BTIG Research increased their target price on shares of Cullinan Oncology from $20.00 to $30.00 and gave the stock a buy rating in a research report on Wednesday, April 17th. Jonestrading increased their target price on shares of Cullinan Oncology from $22.00 to $26.00 and gave the stock a buy rating in a research report on Wednesday, April 17th. William Blair assumed coverage on shares of Cullinan Oncology in a research report on Monday, April 15th. They set an outperform rating on the stock. Finally, Wedbush assumed coverage on shares of Cullinan Oncology in a research report on Thursday, February 15th. They set an outperform rating and a $30.00 target price on the stock. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of Buy and a consensus target price of $31.00.

Cullinan Oncology Stock Up 4.0 %

Cullinan Oncology stock opened at $28.10 on Wednesday. The stock has a market cap of $1.21 billion, a P/E ratio of -7.62 and a beta of 0.33. Cullinan Oncology has a twelve month low of $7.64 and a twelve month high of $29.12. The company’s 50-day moving average price is $17.69 and its two-hundred day moving average price is $13.34.

Cullinan Oncology (NASDAQ:CGEM) last released its quarterly earnings results on Thursday, March 14th. The company reported ($0.54) earnings per share for the quarter, beating the consensus estimate of ($0.96) by $0.42. Equities analysts anticipate that Cullinan Oncology will post -3.21 earnings per share for the current fiscal year.

Institutional Trading of Cullinan Oncology

Large investors have recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. boosted its position in shares of Cullinan Oncology by 352.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,954 shares of the company’s stock worth $50,000 after acquiring an additional 3,859 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Cullinan Oncology by 1,331.5% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,542 shares of the company’s stock worth $59,000 after acquiring an additional 6,085 shares in the last quarter. Vontobel Holding Ltd. acquired a new stake in shares of Cullinan Oncology during the 4th quarter worth approximately $102,000. Annandale Capital LLC boosted its position in shares of Cullinan Oncology by 20.0% during the 3rd quarter. Annandale Capital LLC now owns 12,000 shares of the company’s stock worth $109,000 after acquiring an additional 2,000 shares in the last quarter. Finally, Bailard Inc. acquired a new stake in shares of Cullinan Oncology during the 4th quarter worth approximately $110,000. Institutional investors and hedge funds own 86.31% of the company’s stock.

Cullinan Oncology Company Profile

Cullinan Oncology, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.